2026 Interim report
Filed with HKEX · Stock code 3880 · · 61 pages · English
Earlier from Medtide
- CPC Scientific Announces U.S. FDA Pre-License Inspection (PLI) Successfully Completed at Its Hangzhou cGMP Manufacturing Facility for Hepcludex® API, Establishing a Proven Track Record Under the Stringent BLA Pathway
- Articles of association
Later from Medtide
- Notification Letter and Reply Form to Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications
- Resignation of executive director
- List of directors and their roles and functions
- Voluntary announcement update on the strategic expansion of large-scale peptide CDMO production capacity
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Follow Medtide into a list and get an email when it puts out news.
Follow Medtide